Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 – Jerusalem
Researcher: Prof. Dinorah Friedmann-Morvinski
Current Role & Affiliation
Title/Position: Associate Professor
Institution: Tel Aviv University
Email: dino@tauex.tau.ac.il
Phone: 058-6310783
Prof. Friedmann-Morvinski leads a research lab focused on aggressive pediatric and adult brain tumors, investigating tumor plasticity, heterogeneity, and the tumor microenvironment.
Research Focus
● Tumor plasticity and heterogeneity
● Tumor-stroma interactions
● CAR T-cell immunotherapy
● Nanomedicine approaches for brain tumors
Current Projects Related to Pediatric Brain Tumors
● Development of CAR T-cell immunotherapies
● Generation of state-of-the-art preclinical glioma models
Laboratory/Research Resources
● Genetically engineered mouse models
● Design and development of CAR T cells
Collaboration Interests
● Immunotherapy strategies
● Patient derived samples/translational research
What You Can Offer Potential Collaborators
● Expertise in CAR T-cell immunotherapy
● Mouse models of pediatric and adult brain tumors
Selected Publications
1. Rousso-Noori, et.al. p32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nat Commun 2021, 12 (1), 3615.
2. Magod P, et al. Exploring the longitudinal glioma microenvironment landscape uncovers reprogrammed pro-tumorigenic neutrophils in the bone marrow. Cell Reports 2021, 35 (5)
3. Friedmann-Morvinski D, et.al.. Monocyte-neutrophil entanglement in glioblastoma. J Clin Invest. 2023 Jan 3;133(1):e163451.
Keywords
Brain Tumors, Immunotherapy, CAR T-Cells, Tumor Microenvironment, Nanomedicine
Brief Bio
Prof. Dinorah Friedmann-Morvinski, an expert in brain tumor research, integrates preclinical models and mechanistic insights to develop innovative therapeutic strategies. Her lab focuses on CAR T-cell immunotherapy and nanomedicine to combat aggressive brain cancers. She earned her Ph.D. in Immunology at the Weizmann Institute and conducted postdoctoral research at the Salk Institute.
